JP2013538856A5 - - Google Patents

Download PDF

Info

Publication number
JP2013538856A5
JP2013538856A5 JP2013531769A JP2013531769A JP2013538856A5 JP 2013538856 A5 JP2013538856 A5 JP 2013538856A5 JP 2013531769 A JP2013531769 A JP 2013531769A JP 2013531769 A JP2013531769 A JP 2013531769A JP 2013538856 A5 JP2013538856 A5 JP 2013538856A5
Authority
JP
Japan
Prior art keywords
interferon
pharmaceutical composition
composition according
pegylated
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013531769A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013538856A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/053681 external-priority patent/WO2012044684A2/en
Publication of JP2013538856A publication Critical patent/JP2013538856A/ja
Publication of JP2013538856A5 publication Critical patent/JP2013538856A5/ja
Pending legal-status Critical Current

Links

JP2013531769A 2010-10-01 2011-09-28 単独治療または他のがん治療と組み合わせたインターフェロンβの使用方法 Pending JP2013538856A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38900910P 2010-10-01 2010-10-01
US61/389,009 2010-10-01
PCT/US2011/053681 WO2012044684A2 (en) 2010-10-01 2011-09-28 Interferon-beta for use as monotherapy or in combination with other cancer therapies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016181104A Division JP2017025086A (ja) 2010-10-01 2016-09-16 単独治療または他のがん治療と組み合わせたインターフェロンβの使用方法

Publications (2)

Publication Number Publication Date
JP2013538856A JP2013538856A (ja) 2013-10-17
JP2013538856A5 true JP2013538856A5 (cg-RX-API-DMAC7.html) 2014-11-13

Family

ID=45890011

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013531769A Pending JP2013538856A (ja) 2010-10-01 2011-09-28 単独治療または他のがん治療と組み合わせたインターフェロンβの使用方法
JP2016181104A Pending JP2017025086A (ja) 2010-10-01 2016-09-16 単独治療または他のがん治療と組み合わせたインターフェロンβの使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016181104A Pending JP2017025086A (ja) 2010-10-01 2016-09-16 単独治療または他のがん治療と組み合わせたインターフェロンβの使用方法

Country Status (9)

Country Link
US (2) US20120082647A1 (cg-RX-API-DMAC7.html)
EP (1) EP2621516B1 (cg-RX-API-DMAC7.html)
JP (2) JP2013538856A (cg-RX-API-DMAC7.html)
AU (2) AU2011308906B2 (cg-RX-API-DMAC7.html)
CA (1) CA2813304A1 (cg-RX-API-DMAC7.html)
ES (1) ES2587837T3 (cg-RX-API-DMAC7.html)
MX (1) MX2013003599A (cg-RX-API-DMAC7.html)
NZ (2) NZ608630A (cg-RX-API-DMAC7.html)
WO (1) WO2012044684A2 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9295669B2 (en) 2010-12-14 2016-03-29 Hoffman La-Roche Inc. Combination therapy for proliferative disorders
EP2958584A1 (en) 2013-02-20 2015-12-30 Yeda Research and Development Co., Ltd. Interferon treatment targeting mutant p53 expressing cells
WO2014130811A1 (en) * 2013-02-22 2014-08-28 Biogen Idec Ma Inc Interferon beta formulation
WO2015150468A2 (en) 2014-04-04 2015-10-08 Ares Trading S.A. Novel ifn beta protein analogs
WO2016078044A1 (zh) * 2014-11-19 2016-05-26 国防医学院 用于治疗癌症的药物组合物以及筛选药物的生物标记
KR102666000B1 (ko) * 2016-07-29 2024-05-14 서울대학교 산학협력단 cFLIP siRNA를 포함하는 인터페론 베타 저항성 암 질환 치료용 또는 감작용 조성물
CN112569358B (zh) * 2019-09-30 2022-06-28 上海生物制品研究所有限责任公司 培干扰素和原癌基因产物靶向抑制剂在协同抑制肿瘤中的应用
CN112569359A (zh) * 2019-09-30 2021-03-30 上海生物制品研究所有限责任公司 培干扰素和原癌基因产物靶向抑制剂在协同治疗肾癌中的应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
RU2185393C2 (ru) 1993-01-06 2002-07-20 Кинертон Лимитед Сложный полиэфир и конъюгат на его основе
CA2345138C (en) * 1998-10-16 2009-12-15 Biogen, Inc. Polymer conjugates of interferon beta-1a and their uses
AU2003254641A1 (en) * 2002-08-28 2004-03-19 Maxygen Aps Interferon beta-like molecules for treatment of cancer
US9125880B2 (en) * 2002-12-26 2015-09-08 Mountain View Pharmaceuticals, Inc. Polymer conjugates of interferon-beta with enhanced biological potency
US20070105887A1 (en) * 2005-11-04 2007-05-10 Wyeth Antineoplastic combinations of temsirolimus and sunitinib malate
WO2007110231A2 (en) * 2006-03-28 2007-10-04 Nautilus Biotech, S.A. MODIFIED INTERFERON-β (IFN-β) POLYPEPTIDES
JP5658565B2 (ja) * 2007-09-12 2015-01-28 ジェネンテック, インコーポレイテッド ホスホイノシチド3−キナーゼ阻害剤化合物と化学療法剤との組合せ、および使用方法

Similar Documents

Publication Publication Date Title
JP2013538856A5 (cg-RX-API-DMAC7.html)
Kleinert et al. Single dose analgesic efficacy of tapentadol in postsurgical dental pain: the results of a randomized, double-blind, placebo-controlled study
ECSP077356A (es) Forma termodinámicamente estable de una sal tosilato
JP2012502885A5 (cg-RX-API-DMAC7.html)
HUE035931T2 (hu) N-[2,4-bis(1,1-dimetiletil)-5-hidroxipenil]-1,4-dihidro-4-oxokinolin-3-karboxamid gyógyszerészeti készítménye és annak alkalmazása
AR067701A1 (es) Metodos y composiciones utiles para la preparacion de inhibidores del contransportador de sodio y glucosa 2
MX2009002642A (es) 4-[4-({[4-cloro-3-(trifluorometil)fenil]carbamoil}amino)-3-fluoro fenoxi]-n-metilpiridina-2-carboxamida monohidrato.
JP2011513196A5 (cg-RX-API-DMAC7.html)
BR112013026706A2 (pt) composições nutricionais compreendendo ácido alfa-hidroxi-isocaproico
JP2015511632A5 (cg-RX-API-DMAC7.html)
BR112014004963A2 (pt) sal de colina do composto anti-inflamatório ciclobutanodiona substituído
EP2210601A4 (en) AGAINST TIREDNESS WITH AN AMINO ACID COMPOSITION
JP2015533163A5 (cg-RX-API-DMAC7.html)
BR112012017691A2 (pt) nova composição
WO2012090225A3 (en) Novel cocrystals / molecular salts of metformin with oleoylethanolamide as an effective anti-diabetic + anti- obesity agent
NO20064050L (no) Anvendelse av agomelatin for a oppna medikamenter tiltenkt for behandlingen av sovnforstyrrelser i den deprimerte pasient
JP2011068692A5 (cg-RX-API-DMAC7.html)
MX2013006031A (es) Formulacion liposomal de dalcetrapib.
SG143203A1 (en) Use of agomelatine in obtaining medicaments intended for the treatment of smith-magenis syndrome
CN103655242A (zh) 水解小麦蛋白洗发露
CY1111257T1 (el) Χρηση της αγομελατινης για τη ληψη φαρμακων προοριζομενων για τη θεραπεια των διπολικων διαταραχων
JP2015509917A5 (cg-RX-API-DMAC7.html)
HRP20161158T1 (hr) Interferon beta za liječenje bolesti donjeg dišnog sustava izazvane gripom
CL2007003216A1 (es) Sal de 2(s), 4(s), 5(s), 7(s)-n-(3-amino-2,2-dimetil-3-oxo-propil)2,7-di(1-metil-etil)-4-hidroxi-5-amino-8-[4-metoxi-3-(3-metoxi-propoxi)fenil]-octanamida; proceso de preparacion; composicion farmaceutica; y uso para la profilaxis o tratamiento de en
NO20064048L (no) Ny assosiasjon mellom agomelatin og en nordadrenalin-reopptaksinhibitor, og farmasoytiske sammensetninger inneholdende den